Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Tumor Burden Assessment With Positron Emission Tomography With

Akhurst, Ng, Larson, O’donoghue, O'Neel, Erdi, Divgi
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Objective: In patients with advanced cancer, total tumor burden affects the likelihood of tumor response and has important implications for prognosis. The aim of this study was to select the optimum 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG PET) tumor uptake parameter to accurately measure tumor burden in advanced metastatic renal cell cancer, in comparison with volumes measured with computed tomography (CT), as a reference test.Materials and Methods: Six patients with metastatic renal cell carcinoma measurable on CT were studied. CT and FDG PET scans were carried out on all patients within 4 weeks prior to their entry into a phase I-II radioimmunotherapy trial. CT-based evaluation of disease extent (tumor volume) and 4 PET-based measurements (standardized uptake value[SUVmax], SUVav, volume, and total lesion glycolysis [TLG]) were performed independently by a radiologist (VN) and a nuclear medicine physician (TA). The degree of correlation between conventional (CT) extent of disease and parameters describing tumor concentration of FDG was then determined.Results: Fifty-seven CT-measurable metastatic lesions in lung, abdomen, and scalp were evaluated in 6 patients. There was a high correlation between CT and FDG PET volume estimates for lesions greater than 5 cm(3) in size. However, a PET-derived parameter that embodies both FDG uptake and lesion size, the TLG, correlated better with CT-derived tumor volume than did FDG PET volume alone.Conclusion: Using CT volume as a gold standard, the optimal PET-based estimate of total tumor burden in patients with metastatic renal cancer is the sum over all lesions of the total lesion glycolysis.
This paper references
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1016/S0009-9260(97)80327-3
FDG PET characterization of renal masses: preliminary experience.
M. Goldberg (1997)
Performance characteristics of a whole-body PET scanner.
T. DeGrado (1994)
10.1016/S1072-7515(97)00012-4
Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients
L. Harrison (1997)
10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding
Y. Erdi (1997)
10.1016/S0022-5347(17)38141-7
Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies.
R. Wahl (1991)
10.1016/S0022-5347(01)64675-5
Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma.
K. Hafez (1997)
Liver metastasis: comparison of 2 methods for reporting of disease in patients receiving chemotherapy.
M. Garant (1999)
[Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
R. Bachor (1995)
10.1055/S-0038-1632343
Functional imaging of Hodgkin's disease with FDG-PET and gallium-67.
P. Willkomm (1998)
10.1002/1097-0142(19850201)55:3<620::AID-CNCR2820550324>3.0.CO;2-7
Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications
F. Marc Stewart (1985)
10.1016/S8756-3282(09)80011-2
Metastatic bone disease: clinical and therapeutic aspects.
J. Body (1992)
10.1200/JCO.1997.15.4.1631
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
M. Janíček (1997)
10.1097/00004728-199611000-00011
The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment.
K. Hopper (1996)
10.1016/S1095-0397(99)00016-3
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
S. Larson (1999)
10.1093/JNCI/91.3.244
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.
H. Scher (1999)
10.2214/AJR.167.4.8819370
Analysis of interobserver and intraobserver variability in CT tumor measurements.
K. Hopper (1996)
10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
V. Ahuja (1998)
[Positron emission tomography in diagnosis of renal cell carcinoma].
R. Bachor (1996)



This paper is referenced by
10.1007/s00261-009-9559-y
Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT
P. Veit-Haibach (2009)
10.2967/jnmt.110.078410
Volume-of-Interest Assessment of Oncologic Response Using 18F-FDG PET/CT: A Phantom Study
Berenice Pérez-López (2011)
Quantification de la fixation tumorale du fluoro-deoxyglucose
D. Huglo (2002)
10.1159/000106575
S-100B and FDG-PET/CT in Therapy Response Assessment of Melanoma Patients
K. Strobel (2007)
10.1118/1.4820445
Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns.
Shan Tan (2013)
10.1007/BF03027391
Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer
Mi Yeon Choi (2005)
10.1088/0031-9155/53/16/001
Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax--a phantom study.
J. Boucek (2008)
10.1007/s12149-011-0478-y
Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer
N. Arslan (2011)
10.1007/s00261-017-1389-8
Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics
M. Gollub (2017)
10.1967/s002449910904
18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
A. Niccoli Asabella (2018)
Early PET / CT Scan Is More Effective Than Response Evaluation Criteria In Solid Tumors in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab
S. Lastoria (2013)
10.2967/jnumed.113.119909
Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab
S. Lastoria (2013)
10.1007/s00259-013-2511-y
Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma
E. Choi (2013)
10.3348/kjr.2013.14.1.1
Prognostic Significance of Volume-Based PET Parameters in Cancer Patients
S. Moon (2013)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
D. Torigian (2011)
10.1007/s12149-015-1034-y
The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET–CT in surgically treated esophageal squamous cell carcinoma
S. Park (2015)
10.1007/s00330-012-2564-5
Combined PET/CT-perfusion in patients with head and neck cancers
P. Veit-Haibach (2012)
10.1016/J.MEDNUC.2006.12.009
Détermination par logique floue des volumes tumoraux en TEP : application au suivi de la radio-immunothérapie des lymphomes
J. M. Esnault (2007)
10.1016/S0140-6736(03)14363-2
Anatomical loci of HIV-associated immune activation and association with viraemia
S. Iyengar (2003)
10.1097/01.aids.0000210603.40267.29
Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation
D. Brust (2006)
Identifying response to therapy in longitudinal PET imaging studies
M. Phillips (2014)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
Year : 2007 S-100 B and FDG-PET / CT in therapy response assessment of melanoma patients
K. Strobel (2009)
Semantic Scholar Logo Some data provided by SemanticScholar